Will Pfizer Inc. Make A Bid For GlaxoSmithKline plc?

Will Pfizer Inc. (NYSE:PFE) bid for GlaxoSmithKline plc (LON: GSK) or AstraZeneca plc (LON: AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

GlaxoSmithKline’s (LSE: GSK) (NYSE: GSK.US) shares have slumped nearly 12%, year to date, a disappointing performance for investors. However, these declines now mean that Glaxo’s total market value is around $116bn, $4bn below the $120bn offer that US pharmaceutical giant Pfizer recently made for Glaxo’s peer, AstraZeneca (LSE: AZN) (NYSE: AZN.US).

With this being the case, it’s entirely possible that Pfizer could come back and make a bid for Glaxo, as the U.S. behemoth searches for bolt-on acquisitions to boost growth. 

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

A great fitgsk

Glaxo and Pfizer would fit together well. The two companies are already cooperating together on some projects, including an HIV joint venture and Glaxo has a strong presence within the vaccines market — something Pfizer is likely to find attractive.

What’s more, Pfizer is bound to be attracted by Glaxo’s low corporate tax rate of only 20%.

However, if Pfizer did to go ahead and launch a bid, Glaxo’s deal with Novartis would fall apart. Indeed, it is unlikely that Pfizer would be attracted to Glaxo’s world-leading consumer healthcare business.

Further, Pfizer would want to gain access to Glaxo’s oncology portfolio, which is being sold to Novartis as part of the deal. 

Then there is the price to consider. It’s likely that Pfizer will have to offer a significant premium to Glaxo’s current share price, in order for the offer to be accepted by investors.

Specifically, City analysts believe that Pfizer would have to offer a premium of 40%, or just under 2,000p per share. A cost to Pfizer of around $170bn, some analysts believe that this figure is too large even for the world’s largest pharmaceutical company.  

astrazenecaSecond attempt 

Meanwhile, it has also been rumoured that Pfizer will make another attempt to buy Astra during the next few months. 

These rumours stem from the fact that Pfizer has recently been facing significant pressure from investors, after unveiling a poor set of half-year results. The company is now under pressure to re-enter negotiations in order to boost its treatment pipeline and flagging profits. 

Pfizer has to wait until November before it can make another unsolicited approach for Astra, although if Astra’s shareholders for the company back to the table, an offer could be made sooner.

And it appears as if Pfizer is running out of time to cut a deal with a UK based company. According to people with knowledge of the matter, the process of tax inversion, where a company shifts its global tax base by buying a smaller rival, may be outlawed within the next 18 months, which would make any deal between Pfizer, Astra or Glaxo less attractive.  

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

These 2 cheap shares dived last week. I’d buy 1 today

Although global stock markets rebounded hard this week, these two cheap shares were left behind in this surge. But I…

Read more »

Female friends enjoying their dessert together at a mall
Investing Articles

Down 40% in 2022, should I buy this 6.3% yield for my Stocks and Shares ISA?

Royal Mail shares have sold off aggressively due to lower parcel volumes and higher-than-expected inflation. Time to add them to…

Read more »

A person holding onto a fan of twenty pound notes
Investing Articles

3 cheap shares with dividend yields of up to 9%

These three cheap FTSE 250 shares all offer market-thrashing dividend yields of up to 8.7% a year. But which would…

Read more »

Twenty pound notes in back pocket of jeans
Investing Articles

3 passive income ideas I’m using today

Our writer shares three passive income ideas he's already using. They're dividend shares -- and he'd consider buying more of…

Read more »

Close-up of British bank notes
Investing Articles

Is now a good time to buy dividend shares?

As economic pressures increase, concerns are growing over dividend shares. Here's why I think it's right to buy now, not…

Read more »

Middle age senior woman sitting at the table at home working using computer laptop clueless and confused expression with arms and hands raised.
Investing Articles

Is now a good time to buy UK stocks?

Markets remain volatile but this Fool doesn't care. He's busy buying great UK stocks on the cheap.

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Investing Articles

A top-quality growth stock to buy on the dip

Growth stocks have sunk this year, with inflationary pressures being the primary reason. Here's one that looks unfairly beaten-down.

Read more »

Gold bullion on a chart
Investing Articles

How I’m protecting my portfolio from a stock market crash in 2022

I am investing in this asset class to protect my portfolio from high inflation, slower growth, or a stock market…

Read more »